INS and cardiovascular disorder: Similar findings have been shown from several real-world studies regarding the efficacy of dulaglutide in lowering glucose with body weight reduction in patients with T2DM, including high-risk patients such as the elderly, patients with stage 3 or 4 chronic kidney disease, and patients with cardiovascular disease [10]; the most recent study was conducted in 2021 for Korean patients with T2DM and evaluated the glycemic efficacy of dulaglutide as an add-on to oral antidiabetic drugs (OADs) and basal insulin for 6 months [2, 16].